Showing results (31-40 of 170) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|March 25, 2010
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine modelAjita V Singh, Michael A Palladino, George Kenneth Lloyd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2011
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsDharminder Chauhan, Ze Tian, Bin Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaTeru Hideshima, James E Bradner, Jason Wong, et al.
Blood|April 2, 2011
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsAjita V Singh, Madhavi Bandi, Noopur Raje, et al.
Experimental Hematology|April 15, 2003
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cellsStephanie Greenstein, Nancy L Krett, Yoshihiro Kurosawa, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2013
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cellsDharminder Chauhan, Arghya Ray, Kristina Viktorsson, et al.
Pageof 17